Skip to main content
Howard Scher, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

HowardIScherMD

Oncology • New York, NY

Cancer Genetics/Cancer Risk Assessment, Genitourinary Oncology, Hematologic Oncology

Head, Biomarker Development Program at Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Scher

Dr. Howard Scher is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from New York University Grossman School of Medicine and has been in practice 47 years. Dr. Scher accepts several types of health insurance, listed below. He is one of 465 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1983
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1976 - 1980
  • New York University School of Medicine
    New York University School of MedicineClass of 1976

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 1977 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Giants of Cancer Care in Genitourinary Oncology 2023
  • Institute for Scientific Information at Clarivate: Highly Cited Researchers 2022
  • Highly Cited Researcher – Top 1% Thomas Reuters, 2014-2022
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outc... 
    2019 ASCO Annual Meeting - 6/1/2019
  • CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

  • Tumor Copy Number Alteration Burden Is a Pan-Cancer Prognostic Factor Associated with Recurrence and DeathSeptember 2018

Press Mentions

  • Triplet Better Than Doublet in mCSPC? Not Always, Say Experts
    Triplet Better Than Doublet in mCSPC? Not Always, Say ExpertsMarch 3rd, 2023
  • Prostate Cancer CTC PSMA Status Could Guide Therapy
    Prostate Cancer CTC PSMA Status Could Guide TherapyOctober 3rd, 2022
  • Taking the Road Less Traveled Toward Clinical Research in Prostate Cancer with Michael J. Morris, MD
    Taking the Road Less Traveled Toward Clinical Research in Prostate Cancer with Michael J. Morris, MDJuly 27th, 2022
  • Join now to see all

Grant Support

  • Spore In Prostate CancerNational Cancer Institute2009–2011
  • Mechanism Based Therapy For Prostate CancerNational Cancer Institute2001–2002
  • Biologic Effects Of 17aa GeldanamycinNational Cancer Institute1999–2000

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Health Net California Large Group PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Howard Scher, Dr. Howard Scher, MD, Dr. H Scher, Dr. Howard I Scher